GlassScriptPhysician profile
Jeffrey C Yonce
NPI 1417480518
$12,832.03
in general payments reported to CMS, 2019-2025
49 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $912 · 2021: $2,743 · 2022: $1,781 · 2023: $2,446 · 2024: $2,607 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,387 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,387.03 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,511.28 | 2020-2025 | |
| Novo Nordisk INC | $1,474.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,072.11 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $935.88 | 2020-2025 | Repatha, Repatha, Evenity |
| Lilly USA, LLC | $898.24 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $603.22 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.03 | 2020-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $461.82 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $422.12 | 2020-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.45 | 2020-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $358.34 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $353.19 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $347.98 | 2020-2025 | Spravato, Xarelto |
| Esperion Therapeutics, INC. | $337.23 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $312.22 | 2021-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $232.00 | 2021-2025 | Veozah |
| Daiichi Sankyo INC. | $176.79 | 2021-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $176.54 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $168.76 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $164.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $152.53 | 2022 | |
| Ardelyx, INC. | $150.74 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $144.15 | 2024 | Voquezna |
| Abbott Laboratories | $129.44 | 2022-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $127.34 | 2025 | |
| Dexcom, INC. | $126.40 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $119.10 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Eisai INC. | $103.81 | 2020-2022 | |
| Amarin Pharma, INC. | $91.82 | 2020-2021 | |
| Allergan, INC. | $91.61 | 2020 | |
| Dynavax Technologies Corporation | $76.87 | 2024 | Heplisav-B |
| Vivus LLC | $76.06 | 2021 | |
| Gilead Sciences, INC. | $61.51 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $58.90 | 2023-2024 | Quviviq |
| Cequr Corporation | $50.00 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $44.54 | 2021-2022 | |
| Boston Scientific Corporation | $41.87 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Edwards Lifesciences Corporation | $38.71 | 2022-2025 | Sapien 3 Ultra Resilia |
| Alkermes, INC. | $35.66 | 2024 | Vivitrol |
| Corium, LLC | $34.01 | 2023 | Azstarys |
| Scynexis, INC. | $27.57 | 2022 | |
| Axsome Therapeutics, INC. | $25.77 | 2024 | Auvelity |
| Ascensia Diabetes Care US INC. | $24.57 | 2025 | |
| Intuity Medical INC | $23.65 | 2022 | |
| Medtronic, INC. | $22.58 | 2024 | Intellis Adaptivestim |
| Lundbeck LLC | $19.92 | 2023 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.80 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2021 | |
| Endo Pharmaceuticals INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Yonce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.